Managed Healthcare Executive articleshttps://www.managedhealthcareexecutive.com/newsManaged Healthcare Executive articles© 2026 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.Wed, 10 Jun 2026 10:33:04 +00005en-us14447https://www.managedhealthcareexecutive.com/newshttps://www.managedhealthcareexecutive.com/logo.webphttps://www.managedhealthcareexecutive.com/view/cagrisema-reduces-hba1c-weight-across-t2d-spectrum-in-reimagine-trials-ada-2026https://www.managedhealthcareexecutive.com/view/cagrisema-reduces-hba1c-weight-across-t2d-spectrum-in-reimagine-trials-ada-2026<![CDATA[The REIMAGINE 1, 2 and 3 trials each met their primary HbA1c end point and confirmatory secondary end points for body weight reduction. ]]>Tue, 09 Jun 2026 20:52:59 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/five-years-later-personalized-mrna-vaccine-cuts-melanoma-recurrence-risk-by-halfhttps://www.managedhealthcareexecutive.com/view/five-years-later-personalized-mrna-vaccine-cuts-melanoma-recurrence-risk-by-half<![CDATA[An individualized mRNA neoantigen vaccine added to pembrolizumab reduced the risk of recurrence by 49% and distant metastasis by 59% in resected high-risk melanoma, with benefits holding through five years of follow-up in a phase 2b trial.]]>Tue, 09 Jun 2026 19:56:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/rebate-and-adherence-concerns-drive-payer-reluctance-on-glp-1-obesity-coveragehttps://www.managedhealthcareexecutive.com/view/rebate-and-adherence-concerns-drive-payer-reluctance-on-glp-1-obesity-coverage<![CDATA[Nearly half of payers not covering GLP-1s for obesity say no price would change their minds on coverage, citing high costs, poor adherence, and weight regain concerns, finds a new survey by PSG. ]]>Tue, 09 Jun 2026 15:53:18 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/lee-kaplan-m-d-discusses-the-metabolic-case-for-survodutide-ada-2026https://www.managedhealthcareexecutive.com/view/lee-kaplan-m-d-discusses-the-metabolic-case-for-survodutide-ada-2026<![CDATA[Phase 3 data show survodutide reduced liver fat by 63% and visceral fat by 34% — effects investigators say go beyond what weight loss alone explains.]]>Mon, 08 Jun 2026 21:31:14 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/researchers-test-single-vaccine-built-to-prevent-future-coronavirus-pandemicshttps://www.managedhealthcareexecutive.com/view/researchers-test-single-vaccine-built-to-prevent-future-coronavirus-pandemics<![CDATA[Cambridge researchers have completed the first human trial of pEVAC-PS, an AI-designed vaccine intended to protect against the entire family of Sarbeco viruses, finding it safe and well tolerated across all dose levels, with modest immune responses that warrant further investigation in a phase 2 trial.]]>Mon, 08 Jun 2026 20:15:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/fda-to-review-biosimilar-of-entyviohttps://www.managedhealthcareexecutive.com/view/fda-to-review-biosimilar-of-entyvio<![CDATA[A decision on Alvotech’s BLA for AVT16 could come as soon as the first quarter of 2027, but Entyvio’s patent doesn’t expire until 2032.]]>Mon, 08 Jun 2026 19:19:58 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/survodutide-cuts-visceral-fat-by-34-liver-fat-by-63-in-phase-3-trials-ada-2026https://www.managedhealthcareexecutive.com/view/survodutide-cuts-visceral-fat-by-34-liver-fat-by-63-in-phase-3-trials-ada-2026<![CDATA[The experimental glucagon/GLP-1 dual agonist showed targeted reductions in metabolically harmful fat alongside meaningful weight loss in two distinct patient populations.]]>Mon, 08 Jun 2026 17:53:17 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/physician-led-or-physician-labeled-how-to-tell-whether-governance-in-value-based-care-is-realhttps://www.managedhealthcareexecutive.com/view/physician-led-or-physician-labeled-how-to-tell-whether-governance-in-value-based-care-is-real<![CDATA[As value-based care continues to evolve, models that embed physician input into decision-making, align incentives and maintain transparency are more likely to sustain improvement.]]>Mon, 08 Jun 2026 15:21:25 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/pivotal-trial-is-recruiting-for-monthly-glp-1-for-weight-loss-ada-2026https://www.managedhealthcareexecutive.com/view/pivotal-trial-is-recruiting-for-monthly-glp-1-for-weight-loss-ada-2026<![CDATA[Pfizer plans 10 phase 3 trials of berobenatide for chronic weight management and obesity-related comorbidities. ]]>Sun, 07 Jun 2026 15:17:50 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/retatrutide-shows-substantial-weight-loss-glycemic-control-in-obesity-and-type-2-diabetes-ada-2026https://www.managedhealthcareexecutive.com/view/retatrutide-shows-substantial-weight-loss-glycemic-control-in-obesity-and-type-2-diabetes-ada-2026<![CDATA[The first triple hormone receptor agonist to reach phase 3 development demonstrated results that researchers say could reshape how clinicians approach obesity and type 2 diabetes treatment.]]>Sun, 07 Jun 2026 01:38:14 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/connect-data-support-cgm-use-in-non-insulin-type-2-diabetes-management-ada-2026https://www.managedhealthcareexecutive.com/view/connect-data-support-cgm-use-in-non-insulin-type-2-diabetes-management-ada-2026<![CDATA[Results presented at ADA 2026 mark the first Level A evidence supporting CGM use in this population.]]>Sat, 06 Jun 2026 20:07:01 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/joanne-mortimer-m-d-on-associations-between-glp-1-use-and-cancer-outcomes-asco-2026https://www.managedhealthcareexecutive.com/view/joanne-mortimer-m-d-on-associations-between-glp-1-use-and-cancer-outcomes-asco-2026<![CDATA[Joanne Mortimer, M.D., of City of Hope breaks down new data linking GLP-1 receptor agonist use to a reduction in mortality across multiple tumor types. ]]>Fri, 05 Jun 2026 19:47:35 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/-a-decade-in-the-making-pashtoon-kasi-m-d-on-what-comes-after-rasolute-302-asco-2026https://www.managedhealthcareexecutive.com/view/-a-decade-in-the-making-pashtoon-kasi-m-d-on-what-comes-after-rasolute-302-asco-2026<![CDATA[RASolute 302 shows daraxonrasib boosts survival in pancreatic cancer, with expanded access and trials pushing earlier use and combination strategies.]]>Fri, 05 Jun 2026 16:29:28 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/new-app-connects-pain-patients-to-doctorshttps://www.managedhealthcareexecutive.com/view/new-app-connects-pain-patients-to-doctors<![CDATA[A new telehealth app called Informed Pain Care connects patients with licensed clinicians for acute pain evaluation and access to treatments nationwide.]]>Fri, 05 Jun 2026 15:56:25 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/pashtoon-kasi-m-d-on-daraxonrasib-s-impact-on-patients-you-have-to-see-it-to-believe-it-asco-2026https://www.managedhealthcareexecutive.com/view/pashtoon-kasi-m-d-on-daraxonrasib-s-impact-on-patients-you-have-to-see-it-to-believe-it-asco-2026<![CDATA[Daraxonrasib, a first-in-class multi-RAS inhibitor, doubles survival in metastatic pancreatic cancer and hints at broader, mutation-agnostic impact.]]>Fri, 05 Jun 2026 15:49:30 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/-fierce-compassion-could-be-key-to-minimizing-shame-in-hiv-patientshttps://www.managedhealthcareexecutive.com/view/-fierce-compassion-could-be-key-to-minimizing-shame-in-hiv-patients<![CDATA[Shame, fueled by stigma, can deter care for HIV patients; recognizing it and responding compassionately can reduce harm, according to Abigail Bachelder, M.P.H., Ph.D., associate psychiatry professor at Boston University Chobanian &amp; Avedisian School of Medicine.]]>Thu, 04 Jun 2026 19:50:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/a-conversation-about-the-connection-between-hiv-and-shame-with-abigail-batchelder-m-p-h-ph-d-clinical-psychologist-and-associate-professor-at-boston-universityhttps://www.managedhealthcareexecutive.com/view/a-conversation-about-the-connection-between-hiv-and-shame-with-abigail-batchelder-m-p-h-ph-d-clinical-psychologist-and-associate-professor-at-boston-university<![CDATA[Abigail Batchelder, M.P.H., Ph.D., clinical psychologist and associate professor at Boston University, explains the effect that shame can have on the healthcare outcomes of HIV patients and why “explicit compassion” is a step in the right direction when treating these individuals. ]]>Thu, 04 Jun 2026 19:12:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/fda-clears-amneal-s-ready-to-use-romidepsin-filling-gap-left-by-teva-s-withdrawalhttps://www.managedhealthcareexecutive.com/view/fda-clears-amneal-s-ready-to-use-romidepsin-filling-gap-left-by-teva-s-withdrawal<![CDATA[Romidepsin is approved to treat adults with cutaneous T-cell lymphoma. Ameal’s generic has received designation for 180 days of exclusivity. ]]>Thu, 04 Jun 2026 15:30:52 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/american-cancer-society-adds-blood-and-stool-tests-to-colorectal-screening-guidelinehttps://www.managedhealthcareexecutive.com/view/american-cancer-society-adds-blood-and-stool-tests-to-colorectal-screening-guideline<![CDATA[Blood-based tests are less sensitive but might increase adherence.]]>Thu, 04 Jun 2026 14:59:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/new-blip-score-may-help-predict-survival-in-patients-with-nsclchttps://www.managedhealthcareexecutive.com/view/new-blip-score-may-help-predict-survival-in-patients-with-nsclc<![CDATA[A newly developed prognostic model may help clinicians better estimate survival in patients with non-small cell lung cancer and brain metastases treated with immune checkpoint inhibitors. ]]>Thu, 04 Jun 2026 13:33:41 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/a-conversation-about-the-challenges-and-benefits-of-hiv-testing-in-church-with-jannette-berkley-patton-ph-d-and-kathryn-derose-ph-d-https://www.managedhealthcareexecutive.com/view/a-conversation-about-the-challenges-and-benefits-of-hiv-testing-in-church-with-jannette-berkley-patton-ph-d-and-kathryn-derose-ph-d-<![CDATA[By partnering with pastors to navigate religious taboos and collaborating with public health agencies, researchers Jannette Berkley-Patton, Ph.D., and Kathryn Derose, Ph.D., demonstrated that African American churches — long-standing pillars of their communities — can serve as trusted, effective sites for HIV testing that reach not only congregants but also the broader community, helping to address the disproportionate impact of HIV on African Americans.]]>Wed, 03 Jun 2026 19:47:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/new-insights-into-adhdhttps://www.managedhealthcareexecutive.com/view/new-insights-into-adhd<![CDATA[An in-depth look into current treatments of ADHD.]]>Wed, 03 Jun 2026 18:46:58 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/dual-target-adc-shows-promising-pfs-signal-in-mcrpc-asco-2026https://www.managedhealthcareexecutive.com/view/dual-target-adc-shows-promising-pfs-signal-in-mcrpc-asco-2026<![CDATA[Tanya Dorff, M.D., breaks down early ABBV-969 data showing strong responses in heavily pretreated mCRPC at ASCO 2026.]]>Wed, 03 Jun 2026 16:36:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/340b-reform-and-drug-shortages-are-among-hospital-pharmacy-concerns-survey-findshttps://www.managedhealthcareexecutive.com/view/340b-reform-and-drug-shortages-are-among-hospital-pharmacy-concerns-survey-finds<![CDATA[Hospital pharmacy leaders cite a potential rebate model transition for the 340B program as one of their biggest worries amid rising manufacturer restrictions and evolving federal compliance requirements.]]>Wed, 03 Jun 2026 16:05:48 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/healthcare-s-workforce-has-a-scale-problem-but-new-model-is-emerginghttps://www.managedhealthcareexecutive.com/view/healthcare-s-workforce-has-a-scale-problem-but-new-model-is-emerging<![CDATA[The workforce challenge in healthcare is not going away. Health systems and health plans can cope with it by rethinking how work can be divided between humans and artificial intelligence. ]]>Wed, 03 Jun 2026 13:28:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/daraxonrasib-trial-exceeds-expectations-after-decades-of-disappointment-in-pancreatic-cancer-drug-developmenthttps://www.managedhealthcareexecutive.com/view/daraxonrasib-trial-exceeds-expectations-after-decades-of-disappointment-in-pancreatic-cancer-drug-development<![CDATA[A study participant in teh trial of daraxonrasib felt like he was part of something special, says UT MD Anderson's Subam Pant, "and he is." ]]>Wed, 03 Jun 2026 00:22:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/fda-approves-differin-epiduo-acne-gel-for-over-the-counter-usehttps://www.managedhealthcareexecutive.com/view/fda-approves-differin-epiduo-acne-gel-for-over-the-counter-use<![CDATA[The FDA has approved Epiduo for over-the-counter use, a combination acne gel previously available only by prescription, a decision experts say could expand access to effective treatment for the millions of Americans who face cost and logistical barriers to dermatological care.]]>Tue, 02 Jun 2026 17:53:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/brukinsa-provides-long-term-disease-control-in-chronic-lymphocytic-leukemiahttps://www.managedhealthcareexecutive.com/view/brukinsa-provides-long-term-disease-control-in-chronic-lymphocytic-leukemia<![CDATA[Real-world data presented at ASCO also show that at 12 month and 24 months, patients treated with Brukinsa had a higher probability of survival than those treated with other BTK inhibitors.]]>Tue, 02 Jun 2026 15:52:54 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/peterson-philanthropies-stands-up-health-analytics-company-for-employershttps://www.managedhealthcareexecutive.com/view/peterson-philanthropies-stands-up-health-analytics-company-for-employers<![CDATA[Peterson Philanthropies announced a commitment of $50 million to set up the public benefit company that will provide employers with healthcare pricing and quality data.]]>Tue, 02 Jun 2026 13:32:00 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articleshttps://www.managedhealthcareexecutive.com/view/the-bispecific-era-in-multiple-myeloma-future-directions-written-recaphttps://www.managedhealthcareexecutive.com/view/the-bispecific-era-in-multiple-myeloma-future-directions-written-recap<![CDATA[C. Brooke Adams, Pharm.D., BCOP, of Orlando Health discusses bispecific antibody therapies for multiple myeloma.]]>Mon, 01 Jun 2026 13:57:43 GMTManaged Healthcare ExecutiveusManaged Healthcare Executive Articles